SCHEMBL29173329

SCHEMBL29173329

CNc1nc(Nc2ccc(N3CCOCC3)c(C)c2)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 3/20 0.41
▸ EML4 Q9HC35 7/20 0.39
▸ ALK Q9UM73 7/20 0.39
▸ RET P07949 6/20 0.39
▸ ROS1 P08922 6/20 0.39
▸ FLT3 P36888 6/20 0.39
▸ MAPK9 P45984 5/20 0.39
▸ MAPK10 P53779 5/20 0.39
▸ P2RX3 P56373 2/20 0.36
▸ PKMYT1 Q99640 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ MAPK8 P45983 2/20 0.35
▸ BMPR1B O00238 1/20 0.35
▸ PLK4 O00444 1/20 0.35
▸ CIT O14578 1/20 0.35
▸ AURKA O14965 1/20 0.35
▸ GAK O14976 1/20 0.35
▸ EPHB6 O15197 1/20 0.35
▸ RIPK2 O43353 1/20 0.35
▸ BUB1 O43683 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30206019 1.00 SYK (0.41) SYKEML4ALKRETROS1
SCHEMBL29173341 0.93 ALK (0.44) SYKEML4ALKRETROS1
SCHEMBL30206110 0.93 ALK (0.44) SYKEML4ALKRETROS1
SCHEMBL24944157 0.92 EML4 (0.47) SYKEML4ALKRETROS1
SCHEMBL30205760 0.92 EML4 (0.47) SYKEML4ALKRETROS1
SCHEMBL29173387 0.91 LRRK2 (0.40) SYKEML4ALKRETROS1
SCHEMBL30206045 0.91 FLT3 (0.37) SYKEML4ALKRETROS1
SCHEMBL29173438 0.91 FLT3 (0.37) SYKEML4ALKRETROS1
SCHEMBL30206049 0.91 LRRK2 (0.40) SYKEML4ALKRETROS1
SCHEMBL29173547 0.90 MEN1 (0.34) SYKPKMYT1MAPTBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
Send feedback